Phase II Trial of Sorafenib Combined With Doxorubicin Eluting Bead-Transarterial Chemoembolization (LC Bead-TACE) for Patients With Hepatocellular Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2015
At a glance
- Drugs Doxorubicin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 16 Aug 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 19 Nov 2012 Planned End Date changed from 1 Feb 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 25 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.